Improving the targeting of tubulin-binding agents: Lessons from drug resistance studies

Current Pharmaceutical Design

Volumn 11, Issue 13, 2005, Pages 1719-1733

  Verrills, N M ^a,b   Kavallaris, M ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

Antimitotic; Cancer; Cytoskeleton; Drug resistance; MAP; Microtubules; Stathmin; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA TUBULIN; CARBOPLATIN; CISPLATIN; COLCHICINE; COMBRETASTATIN; CRYPTOPHYCIN DERIVATIVE; CYTOSKELETON PROTEIN; DESOXYEPOTHILONE B; DISCODERMOLIDE; DOCETAXEL; DOXORUBICIN; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; HALICHONDRON DERIVATIVE; ISOPROTEIN; IXABEPILONE; LAULIMALIDE; LS 4477; LS 4559; MICROTUBULE PROTEIN; NAVELBINE; NOCODAZOLE; PACLITAXEL; REGULATOR PROTEIN; RHAZINALAM; SARCODICTYIN DERIVATIVE; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER RESISTANCE; CELL DEATH; CLINICAL STUDY; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIARRHEA; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; MITOSIS INHIBITION; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROTUBULES; TAXOIDS; TUBULIN; VINCA ALKALOIDS;

EID: 18744399859     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764706     Document Type: Review

References (164)

1. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991; 51: 377-401.
2. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51: 2212-22.
3. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
4. Sorger PK, Dobles M, Tournebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997; 9: 807-14.
5. Page AM, Hieter P. The anaphase-promoting complex: new subunits and regulators. Annu Rev Biochem 1999; 68: 583-609.
6. Jordan MA, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Aci USA 1993; 90: 9552-6.
7. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
8. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995; 34: 2203-11.
9. Mitchison TJ, Kirschner M. Dynamic instability of microtubule growth. Nature 1984; 312: 237-42.
10. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8:411-24.
11. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003; 46: 4805-17.
12. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
13. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000; 69: 277-302.
14. Hyams JS, Lloyd CW. eds. Microtubules. Wiley-Liss: New York1994.
15. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178: 207-75.
16. Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 1471: O1-9.
17. Lewis SA, Gu W, Cowan NJ. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell 1987; 49: 539-48.
18. Rowinsky EK, Donehower RC. Antimicrotubule Agents. In: Devita VT, Hellman S, Rosenberg SA (eds.), Cancer Principles and Practice of Oncology. Philadelphia: Lippincott-Raven 1997; 467-83.
19. Pui C-H, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia - current status and future prospectives. Lancet Oncol 2001; 2: 597-607.
20. Haskell CM. Antineoplastic agents. In Cancer Treatment, Ed 4. C.M. Haskell ed. 1995; Philadelphia: W.B. Saunders Co.: 78-165.
21. Rai SS, Wolff J. Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem 1996; 271: 14707-11.
22. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubules. Annu Rev Cell Der Biol 2000; 16: 89-111.
23. Morgan JL. Spooner BS. Immunological detection of microtubule poison-induced conformational changes in tubulin. J Biol Chem 1983; 258: 13127-33.
24. Farrell KW, Wilson L. Tubulin-colchicine complexes differentially poison opposite microtubule ends. Biochemistry 1984; 23: 3741-8.
25. Erickson HP. Negatively stained vinblastine aggregates. Ann NY Acad Sci 1975; 253: 51-2.
26. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 1996; 16: 207-31.
27. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990; 265: 17141-9.
28. Fahy J. Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. J Curr Pharm Des 2001; 7: 1181-97.
29. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001; 60: 225-32.
30. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003; 2: 427-436.
31. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001; 40: 159-73.
32. Hill BT. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des 2001; 7: 1199-212.
33. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001; 84: 290-5.
34. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anti-Canc Agents 2002; 2: 55-70.
35. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumour agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7.
36. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134-6.
37. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5: S3-6.
38. Mogensen MM, Tucker JB. Taxol influences control of protofilament number at microtubule-nucleating sites in Drosophila. J Cell Sci 1990; 97 (Pt 1): 101-7.
39. Andreu JM, Bordas J, Diaz JF, Garcia de Ancos J, Gil R, Medrano FJ, et al. Low resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules. J Mol Biol 1992; 226: 169-84.
40. Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature 1998; 391: 199-203.
41. Nogales E, Whittaker M, Milligan RA, Downing KH. High resolution model of the microtubule. Cell 1999; 96: 79-88.
42. Amos L, Lowe J. How Taxol stabilizes microtubule structure. Chem Biol 1999; 6: R65-9.
43. Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA, et al. 3′(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994; 269: 3132-4.
44. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002; 62: 1935-8.
45. Gerth K, Bedorf N, Hofle G, Irsehik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560-3.
46. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-33.
47. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997; 272: 2534-41.
48. Muhlradt PF, Sasse F. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res 1997; 57: 3344-6.
49. Ojima I, Chakravarty S, Inoue T, Lin S, He L, Horwitz SB, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 1999; 96: 4256-61.
50. He L, Jagtap PG, Kingston DG, Shen HJ, Orr GA, Horwitz SB. A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry 2000; 39: 3972-8.
51. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired pacitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-25.
52. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904-9.
53. Nicolaou KC, Finlay MR, Ninkovic S, King NP, He Y, Li T, et al. Synthesis and biological properties of C12, 13-cyclopropyl-epothilone A and related epothilones. Chem Biol 1998; 5: 365-72.
54. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo anlitumor activity. Biochim Biophys Acta 2000; 1470: M79-91.
55. Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 1998; 95: 9642-7.
56. Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998; 95: 15798-802.
57. Baird RD, Kaye SB. Drug resistance reversal-are we getting closer? Eur J Cancer 2003; 39: 2450-61.
58. McDaid HM, Mani S, Shen H, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during phase I clinical study. Clin Cancer Res 2002; 8: 2035-43.
59. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10: 1289-98.
60. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat 2001; 4: 392-401.
61. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-65.
62. He L, Yang CP, Horwitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001; 1: 3-10.
63. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003; 10: 597-607.
64. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (Review). Int J Oncol 2002; 21: 621-8.
65. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22: 7280-95.
66. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 1999; 274: 23875-82.
67. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-9.
68. Ojima I, Ferlini C. New insights into drug resistance in cancer. Chem Biol 2003; 10: 583-4.
69. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003; 63: 1207-13.
70. Anthony RG, Waldin TR, Ray JA, Bright SW, Hussey PJ. Herbicide resistance caused by spontaneous mutation of the cytoskeletal protein tubulin. Nature 1998; 393: 260-3.
71. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786-93.
72. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004; 5: 158-64.
73. Lu Q, Luduena RF. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem 1994; 269: 2041-7.
74. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997; 36: 3554-62.
75. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 1994; 91: 11358-62.
76. Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 1990; 265: 1794-9.
77. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77: 562-6.
78. Kavallaris M, Kuo DY, Burkhart CA, Regi DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282-93.
79. Kyu-Ho Han E, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, et al. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 2000; 36: 1565-71.
80. Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001; 7: 2912-22.
81. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003; 56: 45-56.
82. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9: 2992-7.
83. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999; 80: 1020-5.
84. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003; 22: 9087-96.
85. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004; 25: 22-8.
86. Carles G, Braguer D, Dumontet C, Bourgarel V, Goncalves A, Sarrazin M, et al. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 1999; 80: 1162-8.
87. Verdier-Pinard P, Wang F, Burd B, Angeletti RH, Horwitz SB, Orr GA. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 2003; 42: 12019-27.
88. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 2003; 42: 5349-57.
89. Rao S, Aberg F, Nieves E, Band Horwitz S, Orr GA. Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry 2001; 40: 2096-103.
90. Jaffrezou JP, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995; 7: 517-27.
91. Banerjee A. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002; 293: 598-601.
92. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000; 275: 17358-63.
93. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 1995; 270: 31269-75.
94. Verrills NM, Walsh B J, Cobon GS, Hains PG, Kavallaris M. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J Biol Chem 2003; 278: 45082-93.
95. Khan IA, Luduena RF. Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 2003; 21: 3-13.
96. Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002; 3: 341-5.
97. Banerjee A, Kasmala LT. Differential assembly kinetics of alpha-tubulin isoforms in the presence of paclitaxel. Biochem Biophys Res Commun 1998; 245: 349-51.
98. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6: 1978-87.
99. Barlow SB, Gonzalez-Garay ML, Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J Cell Sci 2002; 115: 3469-78.
100. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991; 266: 3987-94.
101. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001; 98: 11737-42.
102. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996; 39: 150-6.
103. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-400.
104. Udom DI, Vignshin DM, Linardou H, Graham H, Palmieri C, Coombes RC. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000; 36: 177-82.
105. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267-72.
106. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, et al. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998; 47: 91-7.
107. Vici P, Amodio A, Di Lauro L, Conti F, Gionfra T, Belli F, et al. First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 2000; 58: 3-7.
108. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000; 18: 695-701.
109. Kano Y, Akutsu M, Suzuki K, Ando J, Tsunoda S. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat 1999; 56: 79-90.
110. Culine S, Roch I, Pinguet F, Romieu G, Bressolle F. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int J Oncol 1999; 14: 999-1006.
111. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule, Int J Cancer 1998; 75: 57-63.
112. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993; 53: 4573-81.
113. Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 1997; 94: 10560-4.
114. Hamilton A, Muggia F. Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology (Huntingt) 2001; 15: 40-3.
115. Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol 2002; 20: 1115-27.
116. Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, et al. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res 2003; 9: 2098-107.
117. Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003; 14: 1518-24.
118. Longley RE, Caddigan D, Harmody D, Gunasekera M, Gunasekera SP. Discodermolide-a new, marine-derived immunosuppressive compound. II. In vivo studies. Transplantation 1991; 52: 656-61.
119. Longley RE, Gunasekera SP, Faherty D, McLane J, Dumont F. Immunosuppression by discodermolide. Ann N Y Acad Sci 1993; 696: 94-107.
120. ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996; 35: 243-50.
121. Hung DT, Chen J, Sehreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996; 3: 287-93.
122. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-22.
123. Martello LA, LaMarche MJ, He L, Beauchamp TJ, Smith AB, Horwitz SB. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chem Biol 2001; 8: 843-55.
124. Nicholson KM, Phillips RM, Shnyder SD, Bibby MC. In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. Eur J Cancer 2002; 38: 194-204.
125. Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998; 16: 1617-24.
126. Nguyen HL, Chari S, Gruber D, Lue CM, Chapin SJ, Bulinski JC. Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth. J Cell Sci 1997; 110: 281-94.
127. Nguyen HL, Gruber D, Bulinski JC. Microtubule-associated protein 4 (MAP4) regulates assembly, protomer-polymer partitioning and synthesis of tubulin in cultured cells. 3 Cell Sci 1999; 112: 1813-24.
128. Murphy M, Hinman A, Levine AJ. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996; 10: 2971-80.
129. Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 1999; 59: 3663-70.
130. Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, et al. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 2002; 8: 1057-64.
131. Hanash SM, Bater LJ, McCurry L, Schwartz SA. Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc Natl Acad Sci USA 1986; 83: 807-11.
132. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM. Characterization of the gene for a proliferation-related phosphoprotein (oneoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 1991; 266: 17747-53.
133. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem Sci 1991; 16: 301-5.
134. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996; 84: 623-31.
135. Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci 1999; 112 (Pt 21): 3713-22.
136. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 1996; 15: 5290-8.
137. Larsson N, Marklund U, Gradin HM, Wandzioch E, Cassimeris L, Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 1997; 17: 5530-9.
138. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 6864-9.
139. Hailat N, Strahler J, Melhem R, Zhu XX, Brodeur G, Seeger RC, et al. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op 18). Oncogene 1990; 5: 1615-8.
140. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001; 114: 909-16.
141. Rodriguez OC, Schaefer AW, Mandato CA, Forscher P, Bement WM, Waterman-Storer CM. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat Cell Biol 2003; 5: 599-609.
142. Danowski BA. Fibroblast contractility and actin organization are stimulated by microtubule inhibitors. J Cell Sci 1989; 93 (Pt 2): 255-66.
143. Kajstura J, Bereiter-Hahn J. Disruption of microtubules induces formation of actin fibrils in density-inhibited 3T3 cells. Cell Biol Int 1993; 17: 1023-31.
144. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-9.
145. Jung HI, Shin I, Park YM, Kang KW, Ha KS. Colchicine activates actin polymerization by microtubule depolymerization. Mol Cells 1997; 7: 431-7.
146. Takeshita H, Kusuzaki K, Ashihara T, Gebhardt MC, Mankin HJ, Hirasawa Y. Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer Lett 1998; 126: 75-81.
147. Smith CD, Carmeli S, Moore RE, Patterson GM. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1343-7.
148. Chan MW, Chiang CD, Song EJ, Yang VC. Effects of cytoskeletal inhibitors on the accumulation of vineristine in a resistant human lung cancer cell line with high level of polymerized tubulin. Cancer Biochem Biophys 1998; 16: 347-63.
149. Zilfou JT, Smith CD. Differential interactions of cytochalasins with P-glycoprotein. Oncol Res 1995; 7: 435-43.
150. Gavin RH. Microtubule-microfilament synergy in the cytoskeleton. Int Rev Cytol 1997; 173: 207-42.
151. Goode BL, Drubin DG, Barnes G. Functional cooperation between the microtubule and actin cytoskeletons. Curr Opin Cell Biol 2000: 12: 63-71.
152. Liang P, MacRae TH. Molecular chaperones and the cytoskeleton. J Cell Sci 1997; 110: 1431-40.
153. Koyasu S, Nishida E, Kadowaki T, Matsuzaki F, Iida K, Harada F, et al. Two mammalian heat shock proteins, HSP90 and HSP100, are actin-binding proteins. Proc Natl Acad Sci USA 1986; 83: 8054-8.
154. Macejak DG, Luftig RB. Stabilization of actin filaments at early times after adenovirus infection and in heat-shocked cells. Virus Res 1991; 19: 31-45.
155. Baas PW, Pienkowski TP, Cimbalnik KA, Toyama K, Bakalis S, Ahmad FJ, et al. Tau confers drug stability but not cold stability to microtubules in living cells. J Cell Sci 1994; 107: 135-43.
156. Sangrajrang S, Denoulet P, Millot G, Tatoud R, Podgomiak MP, Tew KD, et al. Estramustine resistance correlates with tau overexpression in human prostatic carcinoma cells. Int J Cancer 1998; 77: 626-31.
157. Veitia R, Bissery MC, Martinez C, Fellous A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 1998; 78: 871-7.
158. Walss-Bass C, Prasad V, Kreisberg JI, Luduena RF. Interaction of the betaIV-tubulin isotype with actin stress fibers in cultured rat kidney mesangial cells. Cell Motil Cytoskeleton 2001; 49: 200-7.
159. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123-30.
160. Giganti A, Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res 2003; 5: 511-25.
161. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oneogene 2003; 22: 3548-53.
162. Altaha R, Fojo T, Reed E, Abraham J. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Design 2002; 8(19): 1707-12.
163. De Souza W. Basic cell biology of Trypanosoma cruzi. Curr Pharm Design 2002; 8(4): 269-85.
164. Ng HC, Khoo HE. Cancer-homing toxins. Curr Pharm Design 2002; 8(22): 1973-85.